Immuno-inflammatory disorders (for example, hemolytic anemia, eczema): Which T-cell subset is typically increased in these conditions?

Difficulty: Easy

Correct Answer: T4 cells (CD4+) are greatly increased

Explanation:

Introduction / Context:Immuno-inflammatory disorders often feature dysregulated helper T-cell activity. Conditions such as allergic eczema and certain autoimmune cytopenias are associated with heightened CD4+ T-cell responses and skewed helper subsets (for example, Th2 in atopy), which amplify B-cell activity and inflammatory cascades.

Given Data / Assumptions:

  • Disorders mentioned are driven by exaggerated immune activation.
  • CD4+ T cells orchestrate humoral and cellular inflammation through cytokines.
  • In many textbook contexts, these diseases are linked to increased helper T-cell activity.

Concept / Approach:Elevated helper function increases cytokine production (for example, IL-4, IL-5, IL-13 in atopy) and provides B-cell help, promoting autoantibody formation in hemolytic anemia. Thus, CD4+ levels and activity are often described as increased in these conditions, aligning with classical MCQ framing.

Step-by-Step Solution:

Identify the dominant dysregulated arm → helper T cells.Relate helper skewing (Th2) to eczema and autoantibody support in hemolytic anemia.Choose the option indicating increased T4 (CD4+) cells.

Verification / Alternative check:Clinical immunology describes elevated helper T-cell activity and cytokine signatures in these diseases; targeted therapies often modulate CD4+ cytokines.

Why Other Options Are Wrong:

CD8+ increased or decreased: Not the hallmark pattern emphasized in such MCQs.T4 reduced: Opposite of expected dysregulation.No change: Ignores well-known helper T-cell involvement.

Common Pitfalls:Equating all inflammatory states with CD8+ cytotoxic dominance; many chronic inflammatory and allergic conditions are CD4+ helper driven.

Final Answer:T4 cells (CD4+) are greatly increased.

More Questions from Monoclonal Antibodies

Discussion & Comments

No comments yet. Be the first to comment!
Join Discussion